{
  "nctId": "NCT03187678",
  "briefTitle": "Safety Study of the Switch From Oral Selexipag to Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension",
  "officialTitle": "A Multicenter, Open-label, Single-sequence Cross-over Study to Assess Safety, Tolerability, and Pharmacokinetics of Intravenous Selexipag in Subjects With Stable Pulmonary Arterial Hypertension Switching From an Oral Stable Dose of Selexipag",
  "protocolDocument": {
    "nctId": "NCT03187678",
    "filename": "Prot_000.pdf",
    "label": "Study Protocol",
    "date": "2017-01-27",
    "uploadDate": "2019-04-19T05:28",
    "size": 1279229,
    "downloadUrl": "https://clinicaltrials.gov/api/v2/studies/NCT03187678/document/Prot_000.pdf",
    "hasProtocol": true,
    "hasSap": false,
    "hasIcf": false
  },
  "phase": [
    "PHASE3"
  ],
  "studyType": "INTERVENTIONAL",
  "allocation": "NA",
  "interventionModel": "SINGLE_GROUP",
  "masking": "NONE",
  "enrollmentInfo": {
    "enrollmentCount": 20,
    "enrollmentType": "ACTUAL"
  },
  "timeline": {
    "startDate": "2017-12-04",
    "completionDate": "2018-05-29",
    "primaryCompletionDate": "2018-05-29",
    "firstSubmitDate": "2017-06-09",
    "firstPostDate": "2017-06-15"
  },
  "eligibilityCriteria": {
    "criteria": "Inclusion Criteria:\n\n* Signed informed consent form prior to any study-mandated procedure.\n* Male and female subjects aged from 18 to 75 years (inclusive),\n* Subjects with stable pulmonary arterial hypertension (PAH) defined as WHO Functional Class I-III at Visit 1 and Visit 2, and no change (i.e., introduction or dose change) in PAH-specific medication (i.e., ERA, PDE-5 inhibitor or sGC stimulator) and diuretics in the last 28 days prior to Visit 2.\n* Subjects currently treated with Uptravi® at a stable dose (i.e. unchanged dose) for at least 28 days before Visit 2.\n* Women of childbearing potential must have a negative pregnancy test at Visit 1 (screening) and Visit 2.\n\nExclusion Criteria:\n\n* Pregnant, planning to become pregnant or lactating.\n* Known and documented moderate or severe hepatic impairment.\n* Subjects having received gemfibrozil at any time since initiation of Uptravi®.\n* Treatment with any prostacyclin and prostacyclin analogs within 28 days prior to Visit 1.\n* SBP \\< 90 mmHg at Visit 1 or at Visit 2.\n* Known or suspected uncontrolled hyperthyroidism.\n* Severe renal failure and ongoing or planned dialysis.\n* Any known factor or disease that might interfere with treatment compliance, study conduct, or interpretation of the results.\n* Known concomitant life-threatening disease with a life expectancy \\< 12 months.\n* Treatment with another investigational treatment within 3 months of Visit 1.",
    "healthyVolunteers": false,
    "sex": "ALL",
    "minimumAge": "18 Years",
    "maximumAge": "75 Years",
    "stdAges": [
      "ADULT",
      "OLDER_ADULT"
    ]
  },
  "endpoints": {
    "primary": [
      {
        "measure": "Number of Participants With at Least One Adverse Event (AE)",
        "description": "AE is any untoward medical event that occurs in a participant during the course of the study whether or not considered by the investigator as related to the study treatment.",
        "timeFrame": "From Day 1 to Day 37"
      },
      {
        "measure": "Number of Participants With Prostacyclin-associated Adverse Events",
        "description": "Prostacyclin-associated AE include headache, diarrhea, nausea, vomiting, jaw pain, myalgia, pain in the extremity, flushing and arthralgia.",
        "timeFrame": "From Day 1 to Day 37"
      },
      {
        "measure": "Number of Participants With Adverse Event Related to Injection Site Reactions",
        "description": "This is the number of participants with at least one clinically significant reaction at the injection site (e.g., erythema/redness, tenderness, swelling, induration, hemorrhage at the injection site) occurring on the days of intravenous (iv) selexipag injection.",
        "timeFrame": "From Day 2 to Day 3"
      },
      {
        "measure": "Number of Participants With Prostacyclin-associated AEs Leading to Study Treatment Discontinuation",
        "description": "This is the number of subjects who discontinued the i.v. selexipag treatment due to prostacyclin-associated adverse events (headache, diarrhea, nausea, vomiting, jaw pain, myalgia, pain in the extremity, flushing and arthralgia).",
        "timeFrame": "From Day 2 to Day 3"
      },
      {
        "measure": "Number of Participants With PAH-related Adverse Events",
        "description": "This is the number of participants with at least one AE considered to be related to pulmonary arterial hypertension during the course of the study.",
        "timeFrame": "From Day 1 to Day 37"
      }
    ],
    "secondary": [],
    "other": []
  },
  "complexityMetrics": {
    "eligibilityCriteria": {
      "inclusionCount": 1,
      "exclusionCount": 1,
      "totalCount": 2
    },
    "endpoints": {
      "primaryCount": 5,
      "secondaryCount": 0,
      "otherCount": 0,
      "totalCount": 5
    },
    "studyDesign": {
      "phases": [
        "PHASE3"
      ],
      "isRandomized": false,
      "isMasked": false,
      "interventionModel": "SINGLE_GROUP"
    },
    "overallComplexityScore": 54,
    "complexityCategory": "Complex"
  },
  "collectionDate": "2025-09-22T02:29:14.894Z",
  "dataSource": "ClinicalTrials.gov API v2 - Comprehensive Collection"
}